The CEO recently gave an update concerning this companies progress at a biotech conference in San Francisco. The plan is to complete the fifth cohort by the spring and be ready for stage II development.
They have completed raising $2 million. They intend to raise an additional $2 million via private placements. However, they may need venture capital type financing once the company moves into stage II trials.
The are also proceeding ahead with the animal studies for the use of their antisense drug in difficult breast cancer cases.